Edition:
India

Abbvie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

70.51USD
13 Sep 2019
Change (% chg)

$-0.32 (-0.45%)
Prev Close
$70.83
Open
$71.30
Day's High
$71.51
Day's Low
$70.48
Volume
1,843,967
Avg. Vol
2,198,489
52-wk High
$96.60
52-wk Low
$62.68

Select another date:

Fri, Sep 13 2019

Photo

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

WASHINGTON About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc .

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

WASHINGTON About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc .

Consumer groups, unions urge caution on $63 bln AbbVie deal for Allergan

WASHINGTON, Sept 12 About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc.

AbbVie abandons late-stage lung cancer asset Rova-T

AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage trial for a type of lung cancer. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, but recorded impairment charges of about $4 billion in January after it halted enrolment of a separate study testing the therapy.

UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T

Aug 29 AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage trial for a type of lung cancer.

AbbVie terminates late-stage lung cancer trial

Aug 29 AbbVie Inc on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo.

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

Aug 28 The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

Aug 28 The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

AbbVie prices new rheumatoid arthritis drug at $59,000 a year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

Select another date: